Literature DB >> 20393071

Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.

M Ruhul Quddus1, C James Sung, Cunxian Zhang, W Dwayne Lawrence.   

Abstract

Most endometrial carcinomas contain only 1 Müllerian cell type although the presence of 2 or more cell types within 1 tumor, for example a predominantly low-grade endometrioid carcinoma with a minor component (arbitrarily defined as 30% or less) of high-grade serous and/or clear cell carcinoma, is not uncommon. The current study attempts to evaluate whether the presence of minor serous or clear cell components exerts an adverse effect on the prognosis in stage-I endometrial carcinomas of ''mixed-type.'' The study cases include 22 cases of stage-I endometrioid carcinoma with a minor component of serous carcinoma and 14 cases of endometrioid carcinoma with a minor component of clear cell carcinoma. Minor components were arbitrarily defined as representing anywhere between 5% and 30% of the total tumor. The study cases were compared with 56 cases of histologically pure age-matched and stage-matched endometrioid carcinomas, 6 pure serous carcinomas, and 13 pure clear cell carcinomas. All study and control cases were fully staged. Treatment history and outcome status were obtained and follow-up ranged from 56 to 140 months. Our study suggests that the presence of minor components of serous and clear cell carcinoma, defined as between 5% and 30%, within a mixed-type endometrial carcinoma appears to adversely influence the long-term survival of stage-I tumors, although a larger study is needed to corroborate our findings.

Entities:  

Mesh:

Year:  2010        PMID: 20393071     DOI: 10.1177/1933719110368433

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  12 in total

Review 1.  [New features in the 2014 WHO classification of uterine neoplasms].

Authors:  S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

2.  Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim
Journal:  Cancer       Date:  2016-12-07       Impact factor: 6.860

Review 3.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

4.  Factors prognostic of survival in advanced-stage uterine serous carcinoma.

Authors:  Laura L Holman; Navdeep Pal; David A Iglesias; Pamela T Soliman; Nyla Balakrishnan; Ann Klopp; Russell R Broaddus; Nicole D Fleming; Mark F Munsell; Karen H Lu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2017-04-30       Impact factor: 5.482

5.  Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.

Authors:  L Coenegrachts; D A Garcia-Dios; J Depreeuw; M Santacana; S Gatius; M Zikan; P Moerman; L Verbist; D Lambrechts; Xavier Matias-Guiu; Frédéric Amant
Journal:  Virchows Arch       Date:  2015-02-13       Impact factor: 4.064

6.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma.

Authors:  Sumi Thomas; Yaser Hussein; Sudeshna Bandyopadhyay; Michele Cote; Oudai Hassan; Eman Abdulfatah; Baraa Alosh; Hui Guan; Robert A Soslow; Rouba Ali-Fehmi
Journal:  Arch Pathol Lab Med       Date:  2016-05-03       Impact factor: 5.534

8.  Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Authors:  Bojana Djordjevic; Bryan T Hennessy; Jie Li; Bedia A Barkoh; Rajyalakshmi Luthra; Gordon B Mills; Russell R Broaddus
Journal:  Mod Pathol       Date:  2012-02-03       Impact factor: 7.842

9.  Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment.

Authors:  Oluwole Fadare; Idris L Renshaw; Sharon X Liang
Journal:  J Cancer       Date:  2012-03-10       Impact factor: 4.207

10.  Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.

Authors:  Kate Lawrenson; Elham Pakzamir; Biao Liu; Janet M Lee; Melissa K Delgado; Kara Duncan; Simon A Gayther; Song Liu; Lynda Roman; Paulette Mhawech-Fauceglia
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.